TriSalus Life Sciences, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.30
- 52-Week Range
- $2.17 – $7.95
- Market Cap
- $151.16M
- P/E (TTM)
- —
- EPS (TTM)
- -0.41
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 222.73
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -38.82%
- Gross Margin
- 86.46%
- Operating Margin
- -62.96%
- Profit Margin
- -56.60%
- Current Ratio
- 4.22
- Debt/Equity
- 49.55
- Total Debt
- $33.69M
- Free Cash Flow
- $-11.61M
- Revenue Growth
- 11.30%
- Earnings Growth
- —
- Enterprise Value
- $143.80M
Market Snapshot
About
TriSalus Life Sciences, Inc. is a medical technology company developing innovative interventional oncology devices and therapies. The company focuses on pressure-enabled drug delivery systems designed to improve outcomes for liver cancer patients.